Marijuana Minute: Weekly News Recap

Canopy Growth Corporation Announces Revised Schedule for First Quarter Fiscal 2019 Financial Results Conference Call

SMITHS FALLS, ONAug. 7, 2018 /CNW/ – Canopy Growth Corporation (TSX: WEED) (NYSE: CGC) (“Canopy Growth” or the “Company”) will release its financial results for the first quarter ended June 30, 2018 on August 14, 2018 after financial markets close.

Canopy Growth will host a conference call and audio webcast with Bruce Linton, Chairman & Co-CEO and Tim Saunders, EVP & CFO at 8:00 AM Eastern Time on August 15, 2018 to review the first quarter fiscal 2019 financial results.

Webcast Information
A live audio webcast will be available at:

Calling Information
Toll Free Dial-In Number: 1-888-231-8191
International Dial-In Number (647) 427-7450
Conference ID: 4984819

Replay Information
A replay of the call will be accessible by telephone until 11:59 PM ET on November 13, 2018.
Toll Free Dial-in Number: 1-855-859-2056
Replay Password: 4984819

Full press release:


GW Pharmaceuticals plc Reports Fiscal Third Quarter 2018 Financial Results and Operational Progress

LONDON and CARLSBAD, Calif., Aug. 07, 2018 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (NASDAQ: GWPH), GW, the Company or the Group), the world leader in the development and commercialization of cannabinoid prescription medicines, announces financial results for the third quarter ended 30 June 2018.

“The recent FDA approval of Epidiolex represents a major medical advance for patients with Lennox-Gastaut Syndrome and Dravet syndrome. We anticipate rescheduling to be completed within 90 days of FDA approval and for product launch to take place in the Fall,” stated Justin Gover, GW’s Chief Executive Officer. “In preparation for launch, we have now completed the hiring of our U.S. sales organization and are engaged with patient organizations, physicians and managed care organizations/payors. This approval has been a transformative event for GW, not only opening a new chapter as a commercial-stage company, but also validating and reinforcing our world leadership in cannabinoid science, and the potential of our product pipeline.”


  • Cash and cash equivalents at 30 June 2018 of £334.0 million ($440.2 million) compared to £241.2 million as at 30 September 2017
  • Revenue for the nine months ended 30 June 2018 of £10.7 million ($14.2 million) compared to £6.1 million for the nine months ended 30 June 2017
  • Loss for the nine months ended 30 June 2018 of £136.7 million ($180.2 million) compared to £90.3 million for the nine months ended 30 June 2017

Full press release:


iAnthus to Present at Canaccord’s 38th Annual Global Growth Conference, MJBizCon International and Benzinga Cannabis Capital Conference

NEW YORK and TORONTOAug. 7, 2018 /CNW/ – iAnthus Capital Holdings, Inc.  (“iAnthus” or “the Company”), (CSE: IAN) (OTCQB: ITHUF), which owns, operates, and partners with licensed cannabis operations throughout the United States, is pleased to announce that Julius Kalcevich, Chief Financial Officer, will speak at Canaccord Genuity’s 38th Annual Global Growth Conference in Boston and the inaugural Benzinga Cannabis Capital Conference in Toronto, and Hadley Ford, Chief Executive Officer, will appear on two panels at MJBizCon International.

Mr. Kalcevich’s presentations will take place at the following dates and times:

  • Canaccord Genuity’s 38th Annual Global Growth Conference: Thursday, August 9 at 8:30am ET in Boston, Massachusetts
  • Benzinga Cannabis Capital Conference: Friday, August 17 at 10:20am ET in Toronto, Ontario

Mr. Ford’s panel discussions, both of which are part of the Cannabis Investing Crash Course track at MJBizCon International in Toronto, will take place at the following date and times:

  • International Investing Considerations Panel: Tuesday, August 14 from 11am – 12pm ET
  • Q&A with Investors: Tuesday, August 14 from 4:20 – 5pm ET

Each presentation will offer the investment community an opportunity to learn about iAnthus’ cannabis operations and expansion strategy. Mr. Kalcevich and Mr. Ford will be available for one-on-one meetings at each conference, following their respective presentations.

The Canaccord presentation will be webcast live on the IR Calendar page of the Company’s website at: Investors interested in arranging a meeting should contact their Canaccord representative.

Full press release:


Aurora Cannabis to Acquire Leading Greenhouse Crop Consulting Company, HotHouse Consulting Inc.

EDMONTONAug. 7, 2018 /CNW/ – Aurora Cannabis Inc. (“Aurora” or the “Company”) (TSX: ACB) (OTCQB: ACBFF) (Frankfurt: 21P; WKN: A1C4WM) announced today that it has entered into a letter of intent whereby Aurora intends to acquire the cannabis business of HotHouse Consulting Inc. (“HotHouse”), a provider of advanced greenhouse consulting services.

Founded by industry veteran Laust Dam in 2004, HotHouse specializes in hybrid greenhouse growing techniques. Since its founding, HotHouse has consulted on a variety of agricultural crops but has focused in recent years on the specialized requirements of large scale cannabis production. With more than 70 years of combined experience, HotHouse’s team of consultants currently provide services for approximately 50 customers globally. Upon closing of the acquisition, Laust Dam will join Aurora Larssen Projects (“ALPS”) as VP of Horticultural Development.

Through this acquisition, Aurora enhances ALPS post-construction services offering, providing customers with ongoing support and consulting by HotHouse’s crop specialists. These services will include grower training to ensure ALPS designed facilities continue to run at optimal efficiency following client handover in addition to crop planning, irrigation strategies, control, nutrition, climate and integrated pest management. Aurora and its clients also gain industry leading insight and knowledge of large scale, component-based irrigation systems which offer more precision but require a detailed operational understanding. For example, the systems deployed at Aurora Sky in Alberta require the ability to monitor crop health, determine deficiencies and make corrections while being aware of several interrelating factors. Producing results such as an improvement of just 1% in this area will yield measurable increases in top line annual revenue growth from a facility of Aurora Sky’s scale.

Full press release:


Liberty Health Sciences Doubles Cultivation Capacity With Expansion of Liberty Health Sciences 360º Innovation Campus

TORONTOAug. 7, 2018 /CNW/ – Liberty Health Sciences Inc. (CSE: LHS)(OTCQX: LHSIF) (“Liberty” or the “Company”), a provider of high quality pharmaceutical grade cannabis, announced today that it has doubled its cultivation space in Florida with production commencing at its Liberty Health Sciences 360 Innovation Campus (the “360 Campus”) in Gainesville in response to the growing demand by Florida patients. The Company received permission to commence production at the 360 Campus while a retrofit of the facilities is being completed. The Company’s Chestnut Hill facility continues to operate at full capacity.

The expansion will increase Liberty’s production capacity in the state by an additional 20,000 sq. feet, bringing the total capacity to 41,200 sq. feet. This initial phase of the 360 Campus will be used for the cultivation of premium grade cannabis along with R&D for future genetic study programs.

The next phase of the previously announced retrofit program is scheduled to be completed in November and will add an additional 80,000 sq. feet, which will result in Liberty having the largest production capacity of any medical marijuana producer in Florida. Once the retrofit is fully completed and on-line in early 2019, the Company’s production capacity will increase to approximately 225,000 sq. feet.

The new cultivation space is fully operational and environmentally controlled with sophisticated irrigation systems, grow lighting, air filtration exchange, CO2 dosing, and heating and cooling to ensure maximum production of the marijuana plant.

“Our new cultivation expansion initiative is in direct response to the increased customer demand for our products and unparalleled customer service experience,” said George Scorsis, CEO of Liberty Health Sciences. “I am proud of our team and our ability to be responsive in real-time to our customers as we continue to provide the best care possible across the state of Florida. This major leap in output will put us well ahead of the competition as we lead the way in commercial horticulture and pharmaceutical grade product development.”

Full press release:



Join the largest Cannabis Investing page on Facebook:

To receive text message alerts when new articles are released click here:

Join our Email list:

Follow us on Instagram:

Follow us on Twitter: @CannaInvestor
Like us on Facebook:

Leave a Reply

Your email address will not be published. Required fields are marked *

pour la musculation tamoxifen buylivraison anonyme, prix favorable As a rule, the infection occurs during penetrative sexual intercourse buy metronidazole no prescription moist environment and can remain viable. cialis 20mg rezeptfreider Wirkstoff des Arzneimittels wird nicht verlassen, Zweifel an der Wirksamkeit der Pillen ein bewährtes Medikament zur Behandlung von BPH in einer Dosierung von 10 mg, die Möglichkeit gibt, ein neues Potential des Penis, um zu versuchen buy Retin AThis drug will no doubt help to solve the problem with acne in young people from 16 years, thanks to the active ingredient of this cream you will experience relief, people will stop laughing at you Diagnosticare la causa della disfunzione erettilecomprar cilaiscosì spesso il trattamento può comportare molteplici tecniche. Comprar cialis en línea

Wealthy Venture Capitalist